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Context: The presence of differentiated thyroid cancer inmature cystic teratomas in the ovaries is rare,
and usually incidentally found on surgical pathology specimens. We present a case of simultaneous
intrathyroidal thyroid cancer and thyroid cancer within a struma ovarii, presenting specific diagnostic
challenges.
Case Description: A 55-year-old woman had an intrathyroidal, encapsulated 1.2-cm papillary thyroid
carcinoma, follicular variant, which was resected. Laboratory studies showed an elevated thyroglobulin
level of 35 ng/mL while on suppressive levothyroxine therapy. During preparation for radioactive iodine
ablation, thyroglobulin increased dramatically to 3490 ng/mL. A pretreatment whole-body scan showed
residual traceruptake in the thyroidbed and increased radiotracer uptake in the pelvis that raised concern
for a pelvic metastasis, given the marked thyroglobulin elevation. After ablation, the posttreatment scan
showed intense focal uptake in the pelvis. Single-photon emission computed tomography–computed
tomography confirmed that the tracer uptake corresponded to a right adnexal mass. The patient
underwent a laparoscopic bilateral salpingo-oophorecotomy with pelvic washings. The final pathology of
the right ovary showed papillary thyroid carcinoma arising in amature cystic teratoma. In addition, there
was abundant normal thyroid tissue with colloid surrounding the carcinoma, indicating a source for the
dramatic rise in thyroglobulin levels and suggesting that the ovarian papillary thyroid cancer arosewithin
the teratoma and was not metastatic disease. Thyroglobulin measurements have been undetectable for
5 years since surgery and radioiodine treatment.
Conclusions: Concurrent intrathyroidal thyroid cancer and differentiated thyroid cancer in struma
ovarii are very rare, but can often be distinguished on clinical grounds.
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Struma ovarii is a rare clinical condition comprising thyroid tissue originating in mature
cystic teratomas in the ovaries. It is recognized when more than 50% of the teratoma is
occupied by thyroid tissue. Abdominal pain, bloating, and abnormal menses occasionally lead
to the finding of struma ovarii. The presence of thyroid cancer in struma ovarii is even rarer
and occurs in approximately 0.5% to 5% of cases [1, 2]. The presence of differentiated thyroid
cancer in struma ovarii is usually reported on the pathological examination of the surgical
specimen, and the presence of thyroid cancer both intrathyroidal and within a struma has not
often been reported. We present an unusual case of a patient with a 1.2-cm papillary thyroid
Abbreviation: SPECT-CT, single-photon emission computed tomography–computed tomography.
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cancer of the neck, follicular variant, which subsequently and unexpectedly showed rising
thyroglobulin levels after completion thyroidectomy. There was concern for possible meta-
static disease, and whole-body scanning was performed. Pelvic uptake was found, and the
patient was eventually diagnosed with an additional papillary thyroid cancer originating in
struma ovarii.
1. Case Presentation
A 55-year-old woman was found to have an incidental 2.5-cm nodule in the left lower thyroid
lobe on physical examination. Ultrasound-guided fine-needle aspiration showed “follicular
neoplasm” on cytology. A left hemithyroidectomy was performed and pathology was con-
sistent with a 1.2-cm papillary thyroid carcinoma, follicular variant. The tumor was en-
capsulated and intrathyroidal, and no additional lymph nodes were sampled. The patient had
no family history of thyroid cancer and no personal history of radiation to the head and neck.
The patient underwent a completion thyroidectomy 2 years later, which showed no additional
foci of thyroid cancer. Laboratory studies performed while taking levothyroxine replacement
therapy showed a thyrotropin concentration of 0.82 mIU/L and a thyroglobulin concentration
of 35 ng/mL in the absence of antithyroglobulin antibodies. The patient agreed to undergo
radioactive iodine ablation.
During preparation for the pretreatment I-123 whole-body scan with thyroid hormone
withdrawal, the patient’s thyrotropin concentration increased to 102 mIU/L, but the thy-
roglobulin concentration increased dramatically to 3490 ng/mL. A whole-body scan was
performed and showed residual tracer uptake in the thyroid bed, estimated at 6%, and no
evidence of metastatic disease in the neck or mediastinum [Fig. 1(a)]. There was also in-
creased radiotracer uptake in the pelvis that likely represented radiotracer within the
bladder, but also raised concern for a pelvic metastasis given the marked elevation in thy-
roglobulin. Single-photon emission computed tomography–computed tomography (SPECT-
CT) to confirm the localization was unavailable at the time of the I-123 pretreatment scan.
The patient subsequently received 150-mCi I-131. The posttreatment scan showed intense
activity in the thyroid bed, compatible with recent remnant ablation, as well as intense focal
uptake in the pelvis [Fig. 1(b)]. SPECT-CT scanning was now available and confirmed tracer
uptake that corresponded to a right adnexal mass [Fig. 1(c)]. A pelvic ultrasound showed that
Figure 1. (a) Diagnostic I-123 whole-body scan (pretreatment) scan showing uptake in the
thyroid and right adnexal region. (b) Posttreatment I-131 whole-body scan showing uptake in
the thyroid and right adnexal region. (c) SPECT-CT scan showing uptake in the right adnexa.
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the right adnexal mass was located in the ovary, indicating a possible struma ovarii tumor.
The patient underwent a laparoscopic bilateral salpingo-oopherecotomy with washings.
Final pathology of the right ovary showed papillary thyroid carcinoma (~1.5 cm in greatest
dimension) arising in a mature cystic teratoma (Fig. 2). In addition, there was abundant
normal thyroid tissue with colloid adjacent to the carcinoma, suggesting the papillary thyroid
cancer within the struma arose within the teratoma and was notmetastatic disease. Staining
was positive for TTF-1 and thyroglobulin, and background tissue showed Hu¨rthle-cell
changes with atypia, consistent with a recent history of radioactive iodine ablation. The pel-
vic washings were negative.
Postoperatively, the patient recovered well. Mutation analysis was performed. The
BRAFV600E mutation was negative on both the original 1.2-cm thyroid cancer as well as the
thyroid carcinoma in the struma ovarii. The thyrotropin concentration became suppressed and
the thyroglobulin concentration has been undetectable for 5 years since radioiodine treatment.
2. Discussion
The diagnosis of papillary thyroid cancer originating in struma ovarii is quite rare and has not
often been reported in a patient with a history of intrathyroidal papillary cancer. Multiple
case reports show the incidental finding of papillary thyroid cancer in struma ovarii after
surgery for either gynecological or abdominal symptoms and subsequent discovery of cervical
thyroid cancer [3–6]. One case report described the finding of a benign struma ovarii on I-131
scanning during evaluation and treatment of Graves disease [7]. In our case, the patient had
previously been diagnosed with a follicular variant of papillary thyroid cancer, and the el-
evated and rising thyroglobulin concentration, as well as pelvic uptake on I-123 scanning,
raised concern for metastatic disease, possibly involving the ovaries. Whereas this can usu-
ally be differentiated from struma ovarii based on clinical grounds [4], there is currently no
established definitive marker available for clinical use. Characteristics that can help differ-
entiate between metastatic disease and synchronous tumors are dissemination pattern, site
of ovarian involvement (bilateral vs unilateral), and the presence of teratomatous features
[8]. Zhu et al. [9] have suggested the possibility of measuring CK19 or TTF-1 expression levels,
and others have suggested tumor profiling by oncogene expression [8]. Additionally, magnetic
resonance imaging findings of “multiloculated ovarian cystic mass with solid component and
variable signal intensity between locules” may point toward struma ovarii [4].
A striking finding in this case was the dramatic rise in thyroglobulin concentration
in preparation for radioiodine treatment. Thyroid hormone withdrawal increased the
Figure 2. (a–c) Hematoxylin and eosin staining of right ovary surgical pathology specimen
confirming the presence papillary thyroid carcinoma arising in struma ovarii.
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thyrotropin concentration up to 102 mIU/L and the thyroglobulin to 3490 ng/mL, which
suggested a large source of thyroid-like tissue, such as a metastasis, even when the original
tumor was considered “low risk” according to the American Thyroid Association’s guidelines
[10]. Efforts are ongoing to better classify thyroid cancers in the neck, including the proposed
reclassification of encapsulated follicular variant of papillary thyroid cancer, primarily based
on the indolent clinical behavior [11]. Given that our patient had this variant of papillary
thyroid cancer, metastatic disease was thought to be highly unlikely [12]. In cases of marked
thyroglobulin rise with pelvic uptake on the pretreatment scan, struma ovarii should be
investigated. In addition, despite the abundant “normal” thyroid tissue in the struma ovarii,
the thyrotropin concentration rose appropriately after thyroid hormone withdrawal, dem-
onstrating that the tissue was nonfunctional, or at least unable to produce thyroxine in large
enough amounts to normalize thyrotropin. The reason for this observation is unknown, but
suggests that, although a teratoma can differentiate into thyroid tissue that appears his-
tologically normal and produces thyroglobulin, it is still not fully functional.
Long-term outcome data of thyroid cancer originating in struma ovarii have recently
become available [13]. A retrospective analysis followed 68 patients over 28 years and showed
survival rates of up to 85% over 20 years. Although there are no evidence-based guidelines for
differentiated thyroid cancer in struma ovarii, most authors recommend oophorectomy fol-
lowed by thyroidectomy and radioactive iodine ablation so that thyroglobulin levels can be
monitored as a tumor marker. A case series review, supported by data from the Surveillance,
Epidemiology, and End Results Program database, suggests that amore aggressive approach
may be restricted to patients showing extraovarian or distant metastases [13, 14].
3. Conclusion
Although papillary thyroid cancer originating in struma ovarii can be incidentally found [3, 5,
6, 8], this case highlights the importance of considering struma ovarii as a cause of rising
thyroglobulin measurements after resection of a generally low-risk papillary thyroid cancer.
Any pelvic uptake on radioactive iodine imaging in the treatment of a patient with established
papillary thyroid cancer of the neckmay also indicate presence of a struma ovarii. The finding
of papillary thyroid cancer originating in struma ovarii can often be clinically distinguished
from papillary thyroid cancer of the neck, but immunohistochemical and molecular char-
acterization techniques may be helpful in the management of these rare cases.
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